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INTRODUCTION 
It is common for individuals with rheumatoid arthritis ( R A ) to exhibit an anemia 
of chronic disease, thrombocytosis, and other laboratory changes consistent with 
inflammation such as an elevated erythrocyte sedimentation rate ( E S R ) and or C-reactive 
protein ( C R P ) . Chrysotherapy, along with other slow acting drugs used in the treatment of 
RA, may partially or completely correct certain abnormal laboratory tests, although these 
changes may take several months to become apparent. 1 Several studies have equated C R P , 
ESR, platelet count, and radiographic changes withr extent or severity of disease. 
Similarly, correlations of laboratory values with each other have also been attempted in 
order to quantitate disease activity or to provide diagnostic aids in a sample RA 
population. 
<t 
Analysis of the efficacy of antirheumatic drugs in rheumatoid arthrtis ( R A ) is a 
difficult task for several reasons. F i r s t , the disease undergoes exacerbations and 
remissions with or without drug therapy. Second, the variability in disease from one 
patient to the next may range from a rapidly crippling, painful, disfiguring malady to a 
slower, milder variant of ( R A ) manifested as a painful, yet nonerosivedisease. Third, 
time to response to gold therapy and other slow acting drugs is long. Up to six months is 
required in certain individuals, to detect objective improvement. Fourth, response to 
chrysotherapy is variable, ranging from none to therapeutic remission on xcasion. Thus, 
measuring drug effect is difficult and assessment is currently based on clinical variables, 
laboratory variables, and patient and physician assessment over long periods of time. The 
compilation of several of the clinical measurements frequently has been used to provide an 
overall combined index of clinical response since some indices may improve while others 
regress during the same time period. 7 Evaluation of all of these variables is tedious, 
2 
time-consuming, and often incorporates subjectivity. 
The objective of this report is to assess the relationship between changes in 
selected laboratory variables and clinical outcomes in individuals suffering from RA. 
Controlled trials have demonstrated that chrysotherapy is efficacious in the treatment of 
RA 8 The first widely accepted controlled trial was the double blind, placebo-controlled 
trial conducted by the Empire Rheumatism Council.(ERC). This multicenter trial 
involving almost 200 patients, half of whom received 50mg of gold sodium thiomalate 
(GST) weekly and half of whom received O.Smcg GST weekly (placebo) for six months, 
revealed that active drug was superior to placebo as measured by functional capacity, 
subjective fitness, joint involvement, grip strength, number of analgesic tablets required, 
improvement in hemoglobin concentration, decline in serum rheumatoid factor ( R F ) titer, 
and decline in ESR. 9 , 1 0 
A trial similar to the ERC effort undertaken in the United States by the Cooperating 
Clinics Committee of the American Rheumatism Association demonstrated GST to be 
superior to placebo only in improvement in ESR and grip strength. 1 ' However, only 68 
patients were enrolled, and after withdrawals only 43 patients were available for 
re-evaluation after six months. 
In a two year double blind study in 2 7 RA patients, Sigler and colleagues showed 
that GST-treated patients improved clinically as assessed by joint swelling. ' 2 In 
addition, gold therapy was reported to retard the progression of disease as assessed 
radiographically. No significant difference in hemoglobin, walk times, nor ESR was 
observed over the 24-month period. 
Several controlled studies have also demonstrated that auranofin is effective 
therapy for rheumatoid arthritis. ' 3 - 1 7 ^ a r C j a r i ( j associates compared auranofin 6mg 
3 
daily to placebo and a weekly course of GST in a randomized, double-blind trial in 193 
patients with definite or classical rheumatoid arthritis. 1 5 Of the patients who completed 
20 weeks of therapy, a significant improvement in number of tender joints, joint 
pain/tenderness score, and physician assessment of disease activity was observed for both 
auranofin and GST treated groups as compared to placebo treated patients. Swelling scores 
were improved for both the auranofin and GST-treated group, but were statistically 
significant between first and last visit only for the GST group compared to placebo. 
Duration of morning stiffness, grip strength, number of swollen joints, patient assessment 
of disease activity, and ARA functional class did not show statistical significance among 
treatment groups. Changes in selected laboratory variables were also assessed for all 
patients who completed the trial. The auranofin treated group had improvement in 
thrombocytosis and R F - t i t e r , although not statistically significant from placebo. 
However, improvement in ESR in the AF-treated group was statistically significant from 
placebo. The GST-treated group was statiscally superior to placebo in improvement of 
anemia, thrombocytosis, and R F - t i t e r . 
In summary, the results of these studies demonstrate several points. F i r s t , gold is 
efficacious, and shows favorable results in about one-third of patients who receive it. 1 ® 
Second, gold is toxic. Approximately one-third of patients receiving gold will require 
discontinuation of the drug secondary to adverse effects including rash, stomatitis, 
thrombocytopenia, proteinuria, abnormal liver function tests, gastrointestinal complaints, 
nitritoid reactions, and miscellaneous other side effects within the first 6 months of 
therapy. Third, gold has been categorized as "disease-modifying", based on its ability to 
reduce ESR, platelet count, immune complexes, and R F - t i t e r while increasing hemoglobin, 
hematocrit, and albumin in treated patients. 5 , 1 9 It has no immediate anti-inflammatory 
4 
action, but decreases disease activity over months, and also may improve X - r a y 
f i n d i n g s . 1 2 
Although these studies show some degree of improvement clinically and/or in 
laboratory values, none have attempted to correlate whether patients who respond 
clinically are indeed the same patients who respond with improvement in one or more 
laboratory parameters. If so, does improvement in laboratory manifestations preceed 
clinical improvement, and therefore prove to be useful indicators of subsequent clinical 
response? 
* 
MATERIALS AND METHODS 
This study is a retrospective analysis utilizing prospective data collected from 161 
RA patients who completed a controlled trial conducted by the Cooperative Systematic 
Studies of Rheumatic Diseases (CSSRD). ' ^ Data were retrieved and analyzed using the 
Department of Family and Community Medicine, Division of Biostatistics Hewlett Packard 
3000 computer. Patients were randomized into one of three treatment groups: 1) placebo 
capsule and placebo injection, 2 ) 3mg auranofin capsule twice daily and placebo injection, 
or 3 ) GST injection of lOmg initially, 25mg the second week, and 50mg every week for 19 
weeks in addition to placebo auranofin capsules. At the completion of the original study, 
definition of responders and nonresponders was based on the following criteria which were 
determined a priori. 1 5 
1) Therapeutic remissions were defined as having five or more of the following 
criteria for at least two consecutive months: morning stiffness of less than 15 
minutes, no fatigue, no joint pain by history, no joint tenderness, no joint 
swelling, and Westergren ESR less than 20mm/hr in men and less than 30mm/hr 
5 
in women. 
2 ) Significant joint improvement for joint pain/tenderness or joint swelling was 
defined as improvement of 5 0 £ or more in the number of swollen and/or tender 
joints. Joint swelling was evaluated by the same physician and was completed by 
assessment of 66 joints graded on a scale of 0=none, 1 =detectable synovial 
thickening without loss of bony contours (.mild), 2=loss of distinctness of bony 
contours (moderate), 3=bulging synovial proliferation with cystic characteristics 
(severe). Joint tenderness/pain was also evaluated by the same physician for 66 
joints, and was graded on a scale of 0=none, 1 =positive response on questioning 
( m i l d ) , 2=spontaneous response elicited (moderate), and 3=withdrawal by patient 
on examination severe). Since several jgints may have improved and several 
worsened, the patient showed improvement if the number of joints improved 
exceeded the number of joints worsened by at least 5 0 £ of the joints initially 
involved and capable of response. "Improved" is defined as change in swelling 
(tenderness) to none or improvement from severe to mild. "Worsening" is defined 
as change in a mildly inflamed joint to one severely swollen (tender) or 
involvement of a previously uninvolved joint. For example, if a patient had ten 
swollen (tender) joints initially, and at the conclusion had seven joints improved 
and two worsened during the t r i a l , this response would be significant, but if six 
joints improved and four worsened significant joint improvement would not have 
occurred. 
3) Response was also defined as an improvement in patient assessment of disease 
by at least two grades on a scale of one to five. 
4 ) In addition, the last definition of response was improvement in physician 
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assessment of disease by at least two grades on a scale of one to five. 
For this study, significant improvement in joint swelling (as defined above) was 
used as a sole indicator for definition of clinical response. Data for all variables were 
gathered from visit one (V | ) of the trial and from the final visit (Vj_) of the trial. Change 
in four laboratory values including hemoglobin, R F - t i t e r , platelet count, and ESR was 
recorded for each patient, and median changes for responders and nonresponders were 
compared within each treatment group (placebo,•auranofin, or GST). Change in median 
laboratory values between responders and nonresponders was compared using the Wilcoxon 
rank sum test (Mann-Whitney U test). 
A second comparison of changes in these laboratory values stratified for 
responders and nonresponders was performed within each treatment for only those patients 
who had abnormal laboratory values at visit one ( V 1 ). Abnormal laboratory values were 
defined as: platelet count > 4 5 0 , 0 0 0 / m m 3 , ESR >28mm/hr, RF titer >1 8 0 , 
hemoglobin-males < 14 gm/dl, hemoglobin females < 12 gm/dl. Finally, a Spearman rank 
correlation between the change in number of swollen joints and change in each lab value 
( E S R , platelet count, hemoglobin, R F ) was performed. 
Skewness and kurtosis (normality) determinations were performed for the 
analyses of the total group as well as for the analyses of those patients who had abnormal 
laboratory values at V j. The distribution of the data was found to be non-normal with 
respect to several of the laboratory variables, thus confirming that nonparametric 
analyses were chosen appropriately. 
7 
RESULTS 
Data from 161 patients who completed 20 weeks of therapy with placebo, 
auranofin, or GST were analyzed. Of those who completed the study, 43 were in the placebo 
group, 64 were in the AF group, and 54 were in the 6ST treated group. However, the sums 
of the three groups do not always equal 161 due to missing laboratory values at V j or V L . 
The following ratios represent the number of respoilders (defined by joint swelling count) 
in each therapeutic group: placebo 5 of 43 ( 1 a u r a n o f i n 18 of 64 ( 2 8 f c ) , GST 20 of 
54 ( 3 7 S ) . 
Tables 1, 11, and 111 summarize the change in laboratory values from V j to V|_ for 
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responders and nonresponders within the three treatment groups for all patients who had 
first and last laboratory values recorded. An association between change in clinical 
response and change in any of the laboratory values ( E S R , platelet count, R F - t i t e r , 
hemoblobin) was not found in the placebo-treated group (Table I). For the 
auranofin-treated patients (Table I I ) , the median change in hemoglobin concentration 
increased and R F - t i t e r decreased to a statistically significant degree over the course of the 
study for responders as compared to nonresponders. In GST-treated patients (Table III) , 
the median change in platelet count between responders and nonresponders significantly 
decreased ( p = 0.02) . 
Tables IV ,V and VI summarize changes in laboratory values from V j to V L for 
responders and nonresponders within each treatment group for those patients who had 
abnormal laboratory values at the beginning of the study. No statistically significant 
associations between changes in laboratory variables and clinical outcomes were revealed 
by the analysis, but several observations are worth noting. F i r s t , in auranofin treated 
patients, the median change in R F - t i t e r is no longer significantly different between 
responders and nonresponders (Table V). There is little decrease in number of patients 
evaluated between the total group ( n = 4 5 ) and the group with an abnormal R F - t i t e r at V t 
( n = 40). Second, in GST-treated patients, the median change in platelet count for 
responders and nonresponders was no longer significantly different (Table VI). However, 
the number of patients with thrombocytosis at V | irf this group was substantially lower 
(n = 9) than the total group analysis (n = 52). Lastly, for both AF-treated and 
GST-treated patients, the difference in change in hemoglobin for responders and 
nonresonders approached statistical significance ( p = 0 . 0 7 ) with relatively small 
p 
numbers of patients in the groups ( n = 26 for AF-treated patients, n = 19 for GST-treated 
patients). 
Table VII summarizes the results of the Spearman rank correlation between change 
in number of swollen joints ( V ] - V L ) and change in each laboratory value ( V p V L ) for 
all patients who completed the study. Although several correlations show statistical 
significance ( p < 0 . 0 5 ) , none show a significant correlation coefficient ( r > 0.80). 
Figures I and II exhibit the Spearman correlation of change in hemoglobin versus 
change in joint swelling count for AF and GST treated groups. Although the AF-treated 
group has a p = 0 . 0 4 for change in hemoglobin correlated with change in swelling count, 
the correlation coefficient was not significant ( r = - 0 . 2 7 ) . 
Table VIII summarizes the Spearman rank correlations between change in number 
of swollen joints ( V} - V L ) and change in each laboratory value (V j - V L ) for the group 
with abnormal laboratories at V ] , Similar to the correlations of the total group, there 
were no significant linear relationships although change in hemoglobin in the GST-treated 
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group approached a relationship ( r = - 0 . 6 0 ) . Change in platelet count for the 
GST-treated group and change in hemoglobin for the AF-treated group lost significance in 
the transition from the total group analysis to only those patients with thrombocytosis 
at V j . 
Figures IV and V exhibit the Spearman correlations of change in hemoglobin to 
change in joint swelling count for AF and GST treated groups for the patients with abnormal 
V | laboratory values. These results are similar to the findings in the initial analysis 
(Tables I - VI) looking simply for an association of change between groups. 
t> 
DISCUSSION 
Rheumatoid arthritis is a debilitating disease that follows an unpredictable course, 
often independent of therapy. In this retrospective evaluation we attempted to discern 
whether changes in ESR, platelet count, hemoglobin, and/or R F - t i t e r were reflective of 
clinical response to chrysotherapy in individual patients. 
In the original study and in subsequent analyses of the original study, the following 
changes were demonstrated between first and last laboratory values for the population of 
RA patients who completed the t r i a l . ' 5 No significant change in hemoglobin was found. 
Platelet count decreased in both AF and GST-treated patients although the change was only 
significant in the GST-treated group. ESR increased by a median of 2.5mm/hr in placebo 
treated patients, and significantly decreased by a median of 9mm/hr in AF-treated 
patients, and by a median of 16.5mm/hr in GST-treated patients. 
A separate analysis was used to assess patients who had abnormal values 
(hemoglobin < 12gm/dl, platelet count > 4 5 0 , 0 0 0 / m m 3 , and ESR > 2 8 m m / h r ) at study 
entry. Hemoglobin increased by a median of 1,7gm/dl in GST-treated patients, which was 
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significantly better than the other two groups. Platelet count decreased in the GST group. 
Erythrocyte sedimentation rate decreased by a median of 20mm/hr in AF-treated patients 
and by 23mm/hr in GST-treated patients, which was significantly better than placebo. 
When compared with placebo, both AF and GST showed a decrease in R F , but this was only 
statistically significant for the GST-treated group. 
In this study, changes in laboratory values-in individual RA patients who were 
stratified to responders and nonresponders differed markedly from the original study 
which evaluated the entire group of RA patients. F i r s t , using joint swelling as an indicator 
of clinical response, the association between change in R F - t i t e r and change in hemoglobin 
concentration with clinical outcome from V j to V|_ was found to be significant in the AF 
treated group, unlike the original trial which found only change in ESR to be clinically 
significant. Second, in this study, change of platelet count was significant ( p = 0 . 0 2 ) for 
the GST treated group, but in the population analysis of the original trial the only 
laboratory value that did not change significantly was hemoglobin concentration. Finally, 
in both auranofin and GST-treated patients, change in ESR was found to be significant in the 
original trial , but not in this study when patients were individualized. Interpretation of 
these outcomes is difficult since consistency between both gold-treated groups, and between 
the original trial and this study is lacking. Based on the findings of this study the results 
would most likely be interpreted as showing no association. 
A second analysis utilizing data only from those patients with abnormal laboratory 
values at the onset of the study was performed in order to eliminate a dilutional effect that 
may result from including patients with normal baseline laboratory values. Patients with 
abnormal laboratory values at the beginning of the study might be expected to have greater 
potential for change. In this evaluation no statistical relationship between changes in any 
of the laboratory studies and clinical outcomes was revealed by the analysis. These results 
differ from the findings of the original trial which showed that improvement in all 
laboratory studies (hemoglobin, E S R , platelet count, R F - t i t e r ) in patients with abnormal 
V | laboratories was statistically significant from placebo in GST-treated patients and 
improvement in ESR was significant for auranofin-treated patients. 
In this study both auranofin and GST-treatedpatients had a change in hemoglobin 
concentration which approached statistical significance ( p = 0 . 0 7 ) . This is interesting 
because hemoglobin, unlike ESR and platelet count, undergoes a slower, more gradual 
change due to red cell turnover kinetics. Because the number of patients in the auranofin 
and GST-treated groups decreased substantially when analyzing only patients with 
abnormal V ] laboratory values, perhaps a longer study or a larger patient population may 
have revealed an asociation between change in hemoglobin and clinical outcomes to be 
statistically significant. 
The third part of the study was a correlation of change in respective laboratory 
value ( V j - V [ _ ) to joint swelling count using the Spearman rank correlation. A correlation 
may be a more sensitive indicator of a relationship than the "all or none" analysis 
(responders or nonresponders) which was used in parts I and 11 of the study by using joint 
swelling count as a sole indicator of clinical response. Correlations were performed for all 
patients with V | and V L data who completed the study (Table VII). Table VI shows a 
significant p value ( p <0.05) for the correlation with swelling count for RF and 
hemoglobin in auranofin treated patients; and platelet count in GST-treated patients. 
Although significance was achieved, the r values are far below an acceptable 
level ( r >0.80). 
12 
When the Spearman rank correlation was performed for only patients who had 
abnormal laboratory studies (Table VIII) changes in R F - t i t e r for the auranofin treated 
group and hemoglobin for GST-treated group were statistically significant, but as in the 
previous analysis, correlation coefficients did not indicate a relationship. 
A number of studies have demonstrated Improvement in laboratory parameters as a 
response to chrysotherapy, yet none have attempted to correlate significant laboratory 
improvement with a definition of meaningful clinical improvement. 9 - 1 5 , 2 0 - 2 1 , 2 3 - 2 7 
In the past, some of these laboratory changes have been used in an attempt to explain the 
pathogenesis of RA, yet their significance is poorly understood. 
In summary, the changes observed with the population analyses of RA patients and 
the individual analyses of the same patients are not necessarily the same. Population 
studies may not correlate directly to gold treatment outcome of individual RA patients, but 
rather exhibit general trends. However, because RA patients are such a diverse group, and 
in constant f lux, individual analyses may be an additional alternative to the appropriate 
analyses of data in subsequent studies. 
These findings suggest that laboratory and clinical outcomes may not improve 
simultaneously in individual patients, although change in hemoglobin concentration over 
20 weeks of therapy with either auranofin or GST showed some degree of improvement in 
both the Spearman rank correlation and in looking for a relationship via definition of 
clinical reponse. Lack of an adequate (sensitive and specific) indicator of clinical and/or 
laboratory response, inadequate sample size, or uncontrollable variations may be 
responsible for making a direct association less evident. Joint swelling was chosen for a 
definition of response because it is less subjective than pain/tenderness, is not affected by 
analgesics, and is probably the most relevant clinical variable to assess when potentially 
13 
toxic agents such as chrysotherapy are being evaluated. 
The small sample size and high variability in the laboratory tests also may have 
been responsible for our observations. Table IX presents an a priori calculation 
summarizing the potential of Type 11 error. It is apparent that a large sample size, 
n = 3 9 3 , is needed to detect a s m a l H 2 0 1 ) difference in changes of laboratory variables 
between responders and nonresonders. Even to identify a large difference ( 8 0 1 ) in 
changes in laboratory variables between respondecs and nonresponders at least 26 patients 
were needed in each sample. Thus, the patient population with abnormal laboratory values 
at V 1 was adequate to identify only very high associations. An effect greater than 0.90 
* 
would have been required to decrease the Type 11 error to an acceptable level. 
Further questions such as whether the absolute change in ESR from 80mm/hr to 
60mm/hr represents the same change as a decrease from 60mm/hr to 40mm/hr or 
whether an improvement in hemoglobin from 12gm/dl to 14gm/dl is the same as an 
increase from 14gm/dl to 16gm/dl need to be addressed in the future. The assumption that 
these absolute changes in laboratory determinations have the same clinical significance is 
often made in the statistical analysis of data. 
Recently, Dixon proposed that acute phase reactants ( A P R ' s ) were useful in 
monitoring the antirheumatic potential of new drugs, and that several biochemical 
variables are potentially useful as markers of disease state. 1 9 Dixon analyzed seven 
different drug treatments in 105 RA patients in order to determine if biochemical 
improvement patterns were drug dependent. In fifteen patients who were treated with gold, 
13 of whom responded favorably, correlations between 23 biochemical variables and eight 
clinical measurements were undertaken. ^>19 Significant correlations ( r > 0 . 8 0 , 
p < 0 . 0 1 ) between both laboratory and clinical measurements were found in the gold 
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treated group. Correlations to clinical response were found for ESR and hemoglobin, but 
not for platelet count. R F - t i t e r was not correlated. They concluded that six laboratory 
variables (plasma viscosity, C-reactive protein ( C R P ) , serum sulphydryl level, serum 
histidine, serum IgM, and hemoglobin) be used in assessing antirheumatic drug activity in 
a population of RA patients. Although these findings may be appropriate for a population of 
RA patients, they may not be applicable to the monitoring of individual patients. 
* 
CONCLUSION 
An analysis of the association between changes in specific laboratory variables and 
clinical outcome in individual patients who participated in a prospective, 
placebo-controlled, double-blind, parallel trial comparing placebo, GST, and auranofin 
was performed. Although not statistically significant, change in hemoglobin was associated 
with clinical response (defined as joint swelling count) in patients with an initially 
abnormal hemoglobin. Regardless of whether or not patients were stratified into groups of 
normal or abnormal study entry laboratory values, changes in laboratory variables ( E S R , 
platelet count, R F - t i t e r ) failed to consistently correlate with clinical change in disease 
activity. Thus, based upon results of this study, changes in platelet count, ESR and 
R F - t i t e r s are not predictable markers of clinical improvement in individual RA patients. 
Hemoglobin, however, may correlate to some extent with clinical response although 
further prospective, long-term studies will be needed to confirm this observation. 
S 3 1 9 V 1 
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T A B L E I: Comparison for meaningful improvement between first ( V I ) and last ( V L ) 
laboratory values for PLACEBO-treated patients, excluding missing data. 
Nonresponders Responders 
VJL VL V I - V L V I V L V I -
Erythrocyte Sedimentation Rate ( m m / h r ) 
median 51 48 - 3 * ' 3 5 30 0 
S.D. 23 26 2 4 20 21 34 
range 4 - 1 1 0 1 1 - 1 2 1 ' 5 - 5 8 1 9 - 6 4 
n 33 5 
Platelets ( x 1 0 3 / m m 3 ) 
median 3 1 0 3 3 7 - 2 6 * 253 2 6 9 28 
S.D. 136 163 1 18 123 33 1 2 3 
range 1 2 9 - 7 1 0 1 3 6 - 7 5 8 2 5 1 - 5 0 8 2 3 3 - 3 0 4 
n 36 . 4 
Rheumatoid Factor Titer (number of dilutions) 
median 7 . 3 7 . 6 0 7 . 5 6.0 1.0 





1 - 1 1 7 - 9 
3 
4 - 9 
0 . 7 8 
0.32 
0 . 1 3 
Hemoglobin (gm/dl) 
median 12.5 1 2 . 7 
S.D. 1 . 7 1 . 7 




. 1 - 1 3 . 8 
5 
13.1 - 0 . 4 
1 .3 1.3 
1 0 . 6 - 1 4 . 0 
0.69 
e - p values are f o r the difference in medians f o r responders and 
nonresponders using the M a n n - W h i t n e y U test 
* - negative values indicate a worsening of a given laboratory value 
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T A B L E II: Comparison for meaningful improvement between f i r s t ( V l ) and 
last(VL) laboratory values for AURANOFIN-treated patients, excluding missing data. 
Nonresponders Responders 
V I Y L 
Erythrocyte Sedimentation Rate ( m m / h r ) 
















1 - 9 7 
( x l O 3 / m m 3 ) 
359 3 4 5 
1 1 7 1 1 0 







1 0 - 7 4 
14 
3 3 7 
94 




5 - 4 1 
305 48 
86 92 
1 7 5 - 5 0 2 
0.68 
0.31 





7 . 5 
2.8 
1 - 1 1 
34 




7 . 3 
1.5 
3 - 8 
5.8 
2 . 7 
1-8 




median 1 2 . 5 1 2 . 2 
S.D. 1.9 1.9 
range 9 . 1 - 1 6 . 9 9 . 3 - 1 7 . 1 
n 4 0 






1 1 . 5 - 1 5 . 7 1 1 . 3 - 1 8 . 2 
18 
0.01 
e - p values a r e for the difference in medians f o r responders and 
nonresponders using the M a n n - W h i t n e y U test 
* - negative values indicate a worsening of a given laboratory value 
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T A B L E I I I : Comparison for meaningful improvement between first ( V I ) and last ( V L ) 
laboratory values for GST-treated patients, excluding missing data. 
Nonresponders Responders 
V I VL V I - V L V I Y L V I -
Erythrocyte Sedimentation Rate ( m m / h r ) * 
median 4 2 30 13 40 22 19 
S.D. 29 21 20 29 2 4 25 
range 2 - 1 2 0 2 - 7 1 2 - 1 2 2 4 - 9 3 
n 33 19 
Platelets ( x 1 0 3 / m m 3 ) 
median 331 296 25 . 3 7 0 2 6 4 7 9 
S.D. 109 91 1 1 1 101 63 91 
range 1 6 1 - 6 3 6 1 8 7 - 5 1 7 2 1 7 - 5 4 6 2 0 1 - 3 7 5 
n 33 19 
Rheumatoid Factor Titer (number of dilutions) 
median 8 . 7 7 . 3 1.3 7 . 5 5.3 1.5 
S.D. 2 . 7 2 .4 1.2 2.6 2.2 1.3 
range 1 - 1 1 1 - 9 1 - 1 0 1 - 9 
n 2 2 16 
Hemoglobin (gm/dl) 
median 1 2 . 7 13.0 0.3 13.5 13.5 0.3 
S.D. 1.1 1 .2 1.1 1.6 1.6 1.5 
range 1 0 . 6 - 1 5 . 2 1 1 . 0 - 1 5 . 9 9 . 5 - 1 5 . 6 1 0 . 6 - 1 6.2 





e - p values are for the difference in medians for responders and 
nonresponders using the M a n n - W h i t n e y U test 
* - negative values indicate a worsening of a given laboratory value 
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T A B L E IV: Comparison for meaningful improvement between first ( V I ) and last ( V L ) 
laboratory values for PLACEBO-treated patients with ABNORMAL V1 laboratory values, 
excluding missing data. 
Nonresponders Responders 
V L Y L V I - V L V I VL V I - V L 
Erythrocyte Sedimentation Rate ( m m / h r ) 
median 54 55 - 2 38 28 8 0.68 
S.D. 21 26 2 4 12 20 2 3 
range 3 0 - 1 1 0 1 1 - 1 2 1 3 0 - 5 8 1 9 - 6 4 
n 31 4 
atelets ( x 1 0 3 / m m 3 ) f 
median 501 489 66 508 2 7 3 235 0 . 1 1 
S.D. 7 2 1 7 0 160 t - -
range 4 6 3 - 7 1 0 3 1 7 - 7 5 8 - - -
n 11 1 
Rheumatoid Factor Titer (number of dilutions) 
median 7 . 7 8.0 0.1 7 . 5 6.0 1.0 
S.D. 1 .4 2.1 1 .3 1.2 2.5 1.5 
range 5 - 1 0 2 - 1 1 1 - 8 4 - 9 
n 26 3 
Hemoglobin (gm/dl) 
median 1 1 . 4 1 2 . 3 0.2 1 1 . 7 13.1 1 .4 
S.D. 0.8 1.2 0.8 0.5 1.8 1.3 
range 9 . 8 - 1 2 . 3 9 . 4 - 1 3 . 4 1 1 . 1 - 1 2 . 1 1 0 . 6 - 14 
n 13 3 
e - p values are f o r the difference in medians f o r responders and 
nonresponders using the M a n n - W h i t n e y U test 
* - negative values indicate a worsening of a given laboratory value 
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T A B L E V: Comparison for meaningful improvement between first ( V I ) and last ( V L ) 
laboratory values for AURANOFIN-treated patients with ABNORMAL V1 laboratory values, 
excluding missing data. 
Nonresponders Resoonders 
Y 1 Y L V I - V L - Y 1 Y L V I -
Erythrocyte Sedimentation Rate ( m m / h r ) 
median 60 40 16 41 21 21 
S.D. 30 22 23 13 11 16 
range 3 2 - 1 3 4 1 8 - 9 7 3 0 - 7 4 7 - 4 1 
n 2 7 8 
Platelets ( x 1 0 3 / m m 3 ) 
median 495 4 4 0 38 458 369 104 
S.D. 51 1 0 7 1 2 4 • 54 60 7 7 
range 4 5 5 - 6 0 2 2 0 0 - 5 9 2 4 5 3 - 5 6 8 3 3 8 - 4 7 5 
n 12 4 
Rheumatoid Factor Titer (number of dilutions) 
median 7 . 9 7 . 7 0.6 7 . 5 5.9 1.5 
S.D. 1 .8 2 . 4 1.6 0,9 2 . 4 5 1.9 
range 5 - 1 1 2 - 1 1 6 - 8 1 - 8 
n 30 10 
Hemoglobin (gm/dl) 
median 1 1 . 5 1 1 . 2 - 0 . 6 1 1 . 8 1 2 . 7 0.4 
S.D. 1 . 2 1.1 1 .2 0.6 0.8 0.8 
range 9 . 1 - 1 3 . 7 9 . 3 - 1 3 . 5 1 1 . 5 - 1 3 . 4 1 1 . 3 - • 1 3 . 4 
n 19 7 
J L * 
0 . 6 4 
0.39 
0 . 1 3 
0 . 0 7 
# - p values are for the difference in medians for responders and 
nonresponders using the Mann-Whitney U test 
* - negative values indicate a worsening of a given laboratory value 
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T A B L E V I : Comparison for meaningful improvement between first ( V I ) and last ( V L ) 
laboratory values for GST-treated patients with ABNORMAL V1 laboratory values, 
excluding missing data. 
Nonresponders Responders 
V_L Y L V I - VL V I V L V I - V L 
Erythrocyte Sedimentation Rate ( m m / h r ) * 
median 51 33 22 50 2 4 2 7 
S.D. 2 4 20 19 5 2 7 21 
range 3 0 - 1 2 0 7 - 7 1 3 0 - 1 2 2 5 - 9 3 
n 2 4 13 
Platelets ( x 10 3 / m m 3 ) 
p 
median 5 1 7 355 126 481 330 196 
S.D. 69 1 1 0 155 39 60 48 
range 4 7 5 - 6 3 6 2 1 0 - 4 9 6 4 7 6 - 5 4 6 2 2 7 - 365 
n 5 4 
Rheumatoid Factor Titer (number of dilutions) 
median 8.8 7 . 5 1.5 7 . 7 5.5 1 . 7 
S.D. 1.6 1.6 1.2 1.5 1.5 1.3 
range 5 - 1 1 3 - 9 5 - 1 0 4 - 9 
n 2 0 14 
Hemoglobin (gm/dl) 
median 1 1 . 9 1 2 . 2 0.8 1 1 . 7 13.4 2.0 
S.D. 0 . 7 1 .2 1.3 1.9 1.6 0.5 
range 1 0 . 6 - 1 3 . 2 1 1 . 0 - 1 4 . 9 9 . 5 - 1 3 . 8 1 1 . 5 - •15.3 
n 14 5 
0.64 
0.62 
0 . 7 1 
0 . 0 7 
e - p values are for the difference in medians f o r responders and 
nonresponders using the M a n n - W h i t n e y U test 
* - negative values indicate a worsening of a given laboratory value 
22 
T a b l e V I I : Spearman Rank Correlations Between Change in Swelling Count and Lab Value 
Differences for A L L patients who completed the study 
Placebo Auranofin GST 
r r n r n 
ESR - 0 . 0 6 0 . 7 1 38 0 . 1 5 0.26 56 0 . 1 5 0 . 2 9 52 
Platelet 0 . 3 4 0 . 0 3 40 0.03 0 . 8 2 62 0 . 4 3 0 . 0 0 2 52 
RF 0 . 2 7 0 . 1 1 36 0 . 4 3 ' 0 . 0 0 4 45 0 . 1 6 0.35 38 
Hemoglobin 0 . 1 3 0 . 4 2 39 - 0 . 2 7 , 0.04 58 - 0 . 1 9 0 . 1 7 51 
T a b l e V I I I : Spearman Rank Correlations Between Change in Swelling Count and Lab Value 
Differences for patients with ABNORMAL labs at V1 who completed the study 
Placebo Auranofin GST 
l _a n n r n 
ESR 0.009 0.96 35 0 . 1 1 0.52 35 - 0 . 0 2 0.90 3 7 
Platelets 0.35 0 . 2 6 12 - 0 . 0 4 0.89 16 0 . 4 1 0 . 2 7 9 
RF 0.26 0 . 1 8 2 9 0.41 0.009 40 0 . 2 2 0 . 2 2 34 
Hemoglobin - 0 . 1 8 0.51 16 - 0 . 2 8 0 . 1 6 26 - 0 . 6 0 0 . 0 0 8 19 
23 
T a b l e IX: Sample Size Calculations for Power = 0 . 8 0 or 0 . 9 0 , alpha = 0 . 0 5 , two-tailed 
test for differing effects, assuming sample size and variances equal in each group. Effect 
size (d) is the degree to which a phenomenon is present in a population. Effect size, along 
with sample size, variability, and level of significance are determinants of Type II 
e r r o r . 2 8 
Effect Size ( d ) 
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hemoglobin concentrations at V I . 
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n = 19 
r = -0.60 







0) ' E 











• • • < > 
• • • 
• • • 
• 
-5 - 2 - 1 
Change in Hemoglobin (V I - VL) 
(gm/dl) 
Figure IV: Spearman Rank Correlation of change in 
hemoglobin to change in joint swell ing count in the 
GST-treated group for those patients with abnormal 
hemoglobin concentrations at V I . 
29 
R E F E R E N C E S 
1) Lipsky PE. Remission inducing therapy in rheumatoid arthritis. Am J Med 
1 9 8 3 ; 7 5 ( S u p p l 4 8 ) : 4 0 - 4 8 . 
2 ) Mallya R K , deBeer FC, B e r r y H , Hamilton E D B , Mace B E W , Pepys MB. Correlation of 
clinical parameters of disease activity in rheumatoid arthritis with serum concentration 
of C-reactive protein and erythrocyte sedimentation rate. J Rheumatol 1 9 8 2 ; 9 : 2 2 4 - 2 2 8 . 
3) Hutchinson R M , Davis P , Jayson MIV. Thrombocytosis in rheumatoid arthritis. Ann 
Rheum Dis 1 9 7 6 ; 3 5 : 1 3 8 - 1 4 2 . 
4) Amos RS, Constable T J , Crockson RA, Crockson A P , McConkey B. Rheumatoid arthritis: 
relation of serum C-reactive protein and erythrocyte sedimentation rate to radiographic 
changes. Br Med J 1 9 7 7 ; 1 : 1 9 5 - 1 9 7 . 
5) Dixon J S , Bird HA, Pickup M E , Wright V. A human model screening system for the 
detector of specific antirheumatic activity. Sem Arthritis Rheum 1 9 8 2 ; 1 2 : 1 8 5 - 1 9 0 . 
p 
6) Haataja M , Kalliomaki L. Inter-relationships of laboratory variables in rheumatoid 
arthritis. J Rheumatol 1 9 7 8 , 5 : 2 6 3 - 2 6 6 . 
7 ) Buchanan W W , Tugwell P. Traditional assessments of articular diseases. Clin Rheum 
Dis 1 9 8 3 ; 9 : 5 1 5 - 5 2 9 . 
8) Gottlieb NL. Gold compounds in the rheumatic diseases. In: K e l l e y W , Ruddy S, Sledge 
C, editors. Textbook of Rheumatology, second edition, Philadelphia: W.B. Saunders Co, 
1 9 8 5 : 7 8 9 - 8 0 9 . 
9) The Research Sub-Committee of the Empire Rheumatism Council: Gold therapy in 
rheumatoid arthritis: report of a multi-centre controlled trial. 
Ann Rheum Dis 1 9 6 0 ; 1 9 : 9 5 - 1 1 9 . 
10) The Research Sub-Committee of the Empire Rheumatism Council: Gold therapy in 
rheumatoid arthritis: final report of a multicentre controlled trial. Ann Rheum Dis 
1 9 6 1 ; 2 0 : 3 1 5 - 3 3 4 . 
1 1 ) The Cooperating Clinics Committee of the American Rheumatism Association: a 
controlled trial of gold salt therapy in rheumatoid arthritis. Arthritis Rheum 
1 9 7 3 , 1 6 : 3 5 3 - 3 5 8 . 
1 2 ) Sigler J W , Bluhm GB, Duncan H , Sharp J T , Ensign DC, McCrum WR. Gold salts in the 
treatment of rheumatoid arthritis, a double blind study. Ann Intern Med 
1 9 7 4 ; 8 0 : 2 1 - 2 6 . 
13) Katz W A , Alexander S, Bland J H , et al. The efficacy and safety of auranofin compared 
to placebo in rheumatoid arthritis. J Rheumatol 1 9 8 2 ; 9 (suppl): 1 7 3 - 1 7 8 . 
30 
1 4 ) Bandilla K , Gross D , Gross W , et al. Oral gold therapy with auranofin ( S K & F 
3 9 2 6 2 ) , a multicenter open study in patients with rheumatoid arthritis. J Rheumatol 
1982;9(suppl 8): 1 5 4 - 1 5 9 . 
15) Ward J R , Williams H J , Egger M J , et al. Comparison of auranofin, gold sodium 
thiomalate, and placebo in the treatment of rheumatoid arthritis, a controlled clinical 
trial. Arthritis Rheum 1 9 8 3 ; 2 6 : 1 3 0 3 - 1 3 1 5 . 
1 6 ) Furst DE. Mechanism of action, pharmacology, clinical eficacy, and side effects of 
auranofin - an orally administered organic gold compound for the treatment of rheumatoid 
arthritis. Pharmacotherapy 1 9 8 3 ; 3 : 2 8 4 - 2 9 8 . 
1 7 ) Davis P. Auranofin. Clin Rheum Dis 1 9 8 4 ; 1 0 : 3 6 9 - 3 8 2 . 
* 
18) Ruddy S. The management of rheumatoid arthritis. In: Kelley W , Ruddy S, Sledge C, 
editors. Textbook of Rheumatology, second edition, Philadelphia: Saunders, 
1 9 8 5 : 9 7 9 - 9 9 2 . 
1 9 ) Dixon J S . Biochemical and clinical changes in rheumatoid arthritis: their relation to 
the action of antirheumatoid drugs. Sem Arthritis Rheum 1 9 8 2 ; 1 2 : 1 9 1 - 2 0 7 . 
2 0 ) Finkelstein A E , Walz DT, Batista V, Mizraji M , Roisman F , Misher A. Auranofin. Ann 
Rheum Dis 1 9 7 6 ; 3 5 : 2 5 1 - 2 5 7 . 
2 1 ) Berglof F E , Berglof K , Walz DT. Auranofin: an oral chrysotherapeutic agent for the 
treatment of rheumatoid arthritis. J Rheumatol 1 9 7 8 ; 5 : 6 8 - 7 4 . 
2 2 ) Riskin WG, Gottlieb NL. Gold therapy for rheumatoid arthritis: use of injectable and 
oral preparations. Hosp Formul 1 9 8 5 ; 2 0 : 1 2 3 2 - 1 2 3 7 . 
2 3 ) Brewer E J , Giannini E H , Barkley E. Gold therapy in the management of juvenile 
rheumatoid arthritis. Arthritis Rheum 1 9 8 0 ; 2 3 : 4 0 4 - 4 1 1 . 
2 4 ) Rothermich NO, Philips VK, Bergen W , Thomas MH. Chrysotherapy, a prospective 
study. Arthritis Rheum 1 9 7 6 ; 1 9 : 1 3 2 1 - 1 3 2 7 . 
2 5 ) Bernhard GD. Auranofin treatment for adult rheumatoid arthritis: comparison of 
2mg and 6mg daily dose. J Rheumatol 1982 ;9(suppl 8): 1 4 9 - 1 5 3 . 
2 6 ) S h a r p J T , Lidsky M D , D u f f y J . Clinical responses during gold therapy for rheumatoid 
arthritis- changes in synovitis, radiologically detectable erosive lesions, serum proteins, 
serologic abnormalities. Arthritis Rheum 1 9 8 2 ; 2 5 : 5 4 0 - 5 4 9 . 
2 7 ) Gottlieb N L , Kiem IM, Penneys NS, Schultz DR. The influence of chrysotherapy on 
serum protein and immunoglobulin levels, rheumatoid factor, and antiepithelial antibody 
titers. J Lab Clin Med 1 9 7 5 ; D e c : 9 6 2 - 9 7 2 . 
2 8 ) Cohen J . The concepts of power analysis. In: Cohen J . Statistical Power Analysis for 






Thomas Francis Krol 
8 2 2 Medical Plaza 
Salt Lake City, Utah 8 4 1 1 2 
( 8 0 1 ) 5 8 2 - 5 3 3 9 
Department of Pharmacy Practice 
College of Pharmacy 
University of Utah 
Salt Lake City, Utah 8 4 1 1 2 
( 8 0 1 ) 5 8 1 - 5 9 4 1 
Dateofbirth: September 1 2 , 1961 
# 
Placeof birth: Chicago, Illinois 
Social Security Number: 3 2 7 - 5 0 - 8 2 3 0 
Marital Status: Married: (Cheryl A. Bicanich- Krol) 
Professional licensure: Pharmacist- Utah # 0 3 6 9 0 - 1 7 0 1 - 7 
EDUCATION 
Bachelor of Science in Pharmacy (with honors) - Ferris 
State College, School of Pharmacy, Big Rapids, Michigan, 1984 
Doctor of Pharmacy- University of Utah College of Pharmacy, Salt Lake City, 
Utah, June, 1986 
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TRAINING 
Residency in Clinical Pharmacy Practice, University Hospital, University of Utah 
Specialty Clerkships 
Infectious Disease - 6 weeks 
Neurology-3 weeks 
Clinical Drug Research - 6 weeks 
Clinical Management - 6 weeks 
Clerkships involved responsibility for promoting safe and effective drug therapy 
including monitoring and pharmacokinetic interpretations, daily rounds with 
physicians and physicians in training, case and topic presentations 
Other Residency Components 
-Night call including drug and toxicology information services and patient care , 
responsibilities for University of Utah Hospital and the Intermountain Regional Poison 
Control Center 
-Participate in journal club, case presentations, seminar review, and undergraduate 
teaching 
-Attendance at Institutional Review Board and Pharmacy and Therapeutics Committee 
meetings 
Research 
Topic: Gold, Comparison of Clinical Efficacy with Laboratory Response -
retrospective analysis of prospective data 
Involves identification of a project, development of proposal and protocol, 
presentation of a colloquium, data collection and analysis, writing of results, and 
presentation of a research seminar. 
PROFESSIONAL EXPERIENCE 
Industrial Pharmacy Intern, Lederle Laboratories, Pearl River , New 
York (Summer 1 9 8 3 ) 
A 10 week internship including experience in Research, Product Development, 
Production, Quality Control, Sales and Marketing. Included a two week research 
project involving literature evaluation and company interaction. 
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PROFESSIONAL EXPERIENCE (Continued) 
Pharmacy Intern, Barcus Pharmacy, Oak Lawn, Illinois ( 1 9 8 1 - 1 9 8 4 ) 
A 3 year internship that provided an opportunity to participate in the operation 
of an independently owned pharmacy. Included experience in dispensing, patient 
counseling, recommendation of various nonprescription drug products, and 
inventory control. 
Poison Information Pharmacist, Intermountain Regipnal Poison Control Center, Salt 
Lake City, Utah ( 1 9 8 4 - 1 9 8 5 ) 
A part time job utilizing telephone communication in making recommendations to 
both consumers and health care professionals regarding many types of 
poisonings. 
Teaching Fellow, Department of Pharmacy Practice, University of Utah ( 1 9 8 4 - 1 9 8 6 ) 
Teaching fellowship for undergraduate pharmacy students on 
their core clinical clerkships. 
Teaching Assistant, Department of Biochemical Pharmacology and Toxicology, 
University of Utah ( 1 9 8 5 - 1 9 8 6 ) 
Teaching assistantship for Common Medicines course with 
over 300 college students desiring a basic understanding of 
drugs. 
PUBLICATIONS 
Writer for the Torch ( F er r i s State College school newspaper): Column entitled "You and 
Your Medications", 1 9 8 3 - 1 9 8 4 
Articles included: "Alcohol", "Takingyour medications properly", 
"Diabetes mellitus", "Pain". 
University of Utah Hospital Drug Information Bulletin ( J u l y - August, 1 9 8 5 ) 
Krol TF. Drug Review - Ceftriaxone. Utah Society of Hospital Pharmacists Newsletter, 
1 9 8 5 , Dec 1 2 , vol VIII , no 2. 
Stephenson SH, Krol TF. Anticoagulants and Lupus Anticoagulant Thrombosis. Drugdex 
Consult, accepted for publication 5/86. 
Krol TF. Book Review: A Clinical Manual of Adverse Drug Reactions by Matthews S J , 
Schneiweiss F , Cersosimo R J , Norwalk, Conn: Appleton-Century Crofts, 1986. Hosp 
Form (in press). 
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PRESENTATONS 
"Digoxin Dosing and Pharmacokinetics" presented to surgical attending and resident 
physicians and medical students, University of Utah Hospital, December 1 7 , 1 9 8 5 . 
"Treatment of Tricyclic Antidepressant Overdoses" presented to psychiatry attending and 
resident physicians, medical students, and nurses at Psychiatric Unit , Veterans 
Administration Medical Center, February 2 7 , 1985. 
"Antidepressant Use in Pregnancy" presented to obstetrics and gynecology attending 
and resident physicians and medical students, University of Utah Hospital March 4 , 
1985. 
"Nitroglycerin Transdermal Patches: Current Status" presented to Pharm.D. faculty and 
students in clinical seminar, University of Utah, April 1 7 , 1985. 
"Antiviral drugs/Acyclovir" presented to pediatric attending and resident physicicans 
and medical students at pediatric noon conference, University of Utah Hospital, May 
2 0 , 1 9 8 5 . 
"Digoxin Forever?" presented to Pharm.D. faculty and students in clinical seminar, 
University of Utah, September 1 8 , 1 9 8 5 . 
"Drug interactions and FDA Drug Evaluation" presented to college students in 
a class called "Common Medicines", University of Utah, October 7 , 1985. 
"Digoxin Pharmacokinetics" presented to family practice attending and resident 
physicicans and medical students at education conference, Holy Cross Hospital, Salt Lake 
City, Utah, October 1 7 , 1985. 
"Myocardial Infarction and Chest Pain" presented to the hospital pharmacy staff, Holy 
Cross Hospital, Salt Lake City , Utah, October 2 4 , 1985. 
"Hypertensive Crisis" presented to the hospital staff, Holy Cross Hospital, Salt Lake 
City, Utah, October 2 9 , 1985. 
"Pneumonias" presented to the hospital pharmacy staff, Holy Cross Hospital, 
November 6, 1985. 
"Anemias" presented to the hospital pharmacy staff, Holy Cross Hospital, 
November 1 3 , 1985. 
"Chronopharmacology" presented to Pharm.D. faculty and students in clinical seminar, 
University of Utah, November 1 8 , 1986. 
"Comparison of Complication Rates of Clindamycin Phosphate Infusion (900mg Q 8 H ) 
Diluted vs. Undiluted" presented at Midyear Clinical Meeting, New Orleans, 
December 9, 1985. 
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PRESENTATIONS (Continued) 
"The Use of Aldose Reductase Inhibitors in Diabetic Complications" presented to 
Pharm.D. faculty and students in clinical seminar, University of Utah, 
February 2 6 , 1986. 
AWARDS AND RECOGNITION 
- F i r s t prize for an essay entitled "Drugs", Ferris State College, 1980 
-Omicron Delta Kappa (National Leadership and Honor Society), 1982 
-Order of Omega (National Leadership Society), 1982 
- R h o Chi Pharmacy Honor Society, 1983 
-International Who's Who in Fraternities and Sororities, 1983 
-Who's Who Among Students in America's Universities and Colleges, 1983 
-Nominated to National Dean's List , 1984 
-Graduated with honors from Ferris State College of Pharmacy, 1984 - D r . William C. 
Sunkes Memorial Award (most likely to succeed as voted by fellow students and faculty 
of Ferris State College), 1 984 
-Nuclear Pharmacy Award (outstanding student in nuclear pharmacy), Ferris State College, 
1984 
-Pharmacy Alumni Scholarship, University of Utah, 1 9 8 4 
- E w a r t A . Swinyard Scholarship, University of Utah, 1985 
PROFESSIONAL ORGANIZATIONS 
Kappa Psi Professional Fraternity ( 1 9 7 9 - p r e s e n t ) : 
President ( 1 9 8 2 - 1 9 8 4 ) 
Vice President ( 1 9 8 1 - 1 9 8 2 ) 
Province Officer ( 1 9 8 2 - 1 9 8 4 ) 
Various committee chairmanships 
Interfraternity Council ( 1 9 8 1 - 1 9 8 3 ) : 
Vice President ( 1 9 8 2 - 1 9 8 3 ) 
Professional Fraternity Association ( 1 9 8 2 - 1 9 8 4 ) 
Student American Pharmaceutical Association ( 1 9 8 1 - 1 9 8 4 ) 
Michigan Pharmacists Association ( 1 9 8 1 - 1 9 8 4 ) 
American Society of Hospital Pharmacists ( 1 9 8 3 - p r e s e n t ) 
American Pharmaceutical Association ( 1 9 8 4 - p r e s e n t ) 
Utah Society of Hospital Pharmacists ( 1 9 8 4 - p r e s e n t ) 
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COMMUNITY SERVICE 
-Over-the-Counter Drug Clinic (sponsored by Kappa Psi Fraternity) , Grand Rapids, 
Michigan 1 9 7 9 - 1 9 8 4 
-Diabetes Screening (sponsored by Kappa Psi Fraternity) , Ferris State College, Big Rapids, 
Michigan 1 9 7 9 - 1 9 8 4 
-Hypertension Screening (sponsored by Student American Pharmaceutical Association) 
Ferris State College, Big Rapids, Michigan 1 9 7 9 - 1 9 8 4 
-Counselor, Diabetic Camp (sponsored by Utah Chapter of American Diabetes Association), 
Kamas, Utah, June 1985 
COLLEGE COMMITTEES 
Dean's Advisory Board, Ferris State College School of Pharmacy, 
1 9 8 2 - 1 9 8 4 . 
Curriculum Committee, University of Utah College of Pharmacy, 
1 9 8 5 - 1 9 8 6 . 
